Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $372.8 million.

  • ARS Pharmaceuticals' Liabilities and Shareholders Equity rose 7132.41% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 5158.15%. This contributed to the annual value of $351.2 million for FY2024, which is 5058.79% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Liabilities and Shareholders Equity stood at $372.8 million, which was up 7132.41% from $313.5 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $382.2 million during Q1 2021, with a 5-year trough of $61.4 million in Q4 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $282.4 million, with a median of $281.4 million in 2022.
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Liabilities and Shareholders Equity was 35802.01% (2022), while the steepest drop was 2311.57% (2022).
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Liabilities and Shareholders Equity stood at $61.4 million in 2021, then soared by 358.02% to $281.4 million in 2022, then decreased by 17.14% to $233.2 million in 2023, then skyrocketed by 50.59% to $351.2 million in 2024, then grew by 6.17% to $372.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $372.8 million in Q3 2025, compared to $313.5 million in Q2 2025 and $327.3 million in Q1 2025.